Please Wait.....
Report
Next-Generation Cancer Diagnostics: Technologies and Global Markets
Market Research Report I 2023-05-03 I 166 Pages I BCC Research
Description
Report Scope:
This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.
The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.
An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.
The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).
The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.
Report Includes:
- 15 data tables and 80 additional tables
- An overview of the global market and technologies for next generation cancer diagnostics
- Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
- Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
- Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
- Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.
Executive Summary
Summary:
An increasing number of cancer cases globally is one of the significant factors contributing to industry growth during the forecast period. Technological advancements in diagnostic tests are further expected to fuel industry growth. Moreover, supportive government initiatives and rising awareness are additional factors anticipated to boost growth during the forecast period. For instance, the Biden-Harris administration has set a goal of decreasing the cancer mortality rate by 50% over the next 25 years and enhancing the knowledge surrounding people living with and surviving tumors.
Cancer is one of the leading causes of death worldwide, and the prevalence of the disease has been escalating at an alarming rate. Therefore, healthcare professionals are focusing on developing effective screening and treatment solutions to check prevalence levels. Early screening increases the success rate of treatment regimens. As a result, healthcare agencies and market players, through various awareness programs, are promoting routine check-ups and screenings. For instance, in March 2022, HHS announced funding of $5 million to improve equity in cancer screening at health centers.
The global oncology burden is projected to reach 28.4 million cases in 2040, a 47% growth from 2020. Thus, a rise in the incidence is anticipated to boost the adoption of cancer diagnostic products. In April 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by permitting access to comprehensive testing for all cancer patients globally. The PCC drives diverse initiatives to grow patient access to precision diagnostics using wide-ranging genomic testing, including next generation sequencing (NGS). The founding members of PCC include Novartis, Bayer, Roche, and GlaxoSmithKline.
Advanced diagnostics for cancer represent a significant market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for noninvasive diagnostic assays that can detect cancers earlier, molecularly subtype tumors to guide therapy decisions and monitor cancer recurrence in treated individuals.
Cancer remains the second leading cause of death worldwide despite advances in treatment. Cancer takes a tremendous toll on patients, families, and society. One pressing need in cancer diagnostics is earlier-stage identification, identifying cancer before it has spread to other body parts. Several companies are using advanced diagnostic platforms to develop and validate assays that detect cancer earlier to meet this need. Sanomics, Prenetics, Guardant, Thrive Earlier Detection, AnPac BioMedical, and Grail are notable examples.
A second pressing need in cancer is a more accurate classification of suspicious lesions or nodules (malignant or benign). Correct type leads to better treatment decisions and fewer unnecessary, invasive biopsies. In the case of lung cancer, peripheral lung nodules are very difficult to biopsy, deep within the small branches of the lung, often beyond the reach of the bronchoscope. Needle biopsy is problematic, carrying the risk of lung collapse and infection. New, non-invasive blood-based tests are needed to assess nodules.
Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of Report
1.4 What's New in This Update?
1.5 Information Sources and Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.6 Research Methodology
1.7 Geographic Breakdown
1.8 Analyst's Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
3.1 Overview
3.2 Next Generation Sequencing in Personalized Medicine
3.2.1 Cost-Effective
3.2.2 Samples Required
3.3 NGS in Clinical Oncology
3.3.1 Accurate Detection of Genetic Mutations
3.3.2 Precision Diagnostics
3.3.3 Tumor Genomic Profiling
3.4 Large-Scale Initiatives and Consortia
3.5 Liquid Biopsy Technologies
3.6 Liquid Biopsy as a Market-Driving Force
3.6.1 Key Trends
3.7 Industry
3.8 Diagnostics Overview
3.9 Arrays and Microfluidics (LOAC) Technologies
3.9.1 DNA Microarrays
3.9.2 Protein Microarrays
3.9.3 Microfluidics
3.10 Multiplex Conventional Technologies
3.11 Polymerase Chain Reaction (PCR) Technology
Chapter 4 Cancer Diagnostics Market
4.1 Forces Driving Growth
4.2 Cancer Markets
4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site
4.3.1 Bladder Cancer
4.3.2 Brain Cancer
4.3.3 Breast Cancer
4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis
4.4.1 Screening/Early Detection Market
4.4.2 Diagnostics Market
4.4.3 Therapy Guidance Market
4.4.4 Monitoring Market
4.5 Market for Next-Generation Cancer Diagnostics by Test Platform
4.5.1 PCR Test Platform
4.5.2 NGS Test Platform
4.5.3 Array/Microfluidics Test Platform
4.5.4 Cells and/or EV Capture Test Platform
4.5.5 Multiplex Conventional Test Platform
4.6 Market for Test Platforms by Cancer Site
4.6.1 PCR Test Platform
4.6.2 NGS Test Platform
4.7 Market by Diagnostic Segment
4.7.1 Screening/Early Detection Market
4.7.2 Diagnostics Market
4.7.3 Monitoring Market
4.7.4 Therapy Guidance Market
4.7.5 Breast Cancer Diagnostics
4.7.6 Digestive Cancer Diagnostics
4.7.7 Respiratory and Skin Cancer Diagnostics
Chapter 5 Market Breakdown Application by Cancer Site
5.1 Overview
5.2 Bladder Cancer
5.3 Brain Cancer
5.3.1 Types of Brain Cancer
5.4 Breast Cancer
5.4.1 Risk
5.4.2 Breast Cancer Screening
5.4.3 Prognosis and Pharmacogenetics Tests
5.4.4 Breast Cancer MDx Platforms
5.4.5 Status of Next-Generation Breast Cancer Tests
5.4.6 Treatment
5.5 Gynecologic Cancers
5.5.1 Cervical Cancer
5.5.2 Ovarian Cancer
5.6 Colorectal Cancer
5.6.1 Conventional Colorectal Cancer Screening Tests
5.6.2 Next-Generation Colorectal Cancer Diagnostic Tests
5.7 Cancer Unknown Primary
5.8 Gastric Cancer
5.9 Kidney Cancer
5.10 Hematologic Tests: Leukemia and Myeloma
5.11 Liver Cancer
5.12 Lung Cancer
5.13 Hematologic Tests: Lymphomas
5.14 Melanoma
5.15 Pan-Cancer
5.16 Prostate Cancer
5.17 Thyroid Cancer
Chapter 6 Emerging Technologies
6.1 Overview
6.2 Population Sequencing Programs
6.3 Introduction
6.4 CRISPR
Chapter 7 Evaluation of the Market Based on Geographic Region
7.1 Overview of the Geographical Distribution of the Market
7.2 Overview
7.3 North America
7.4 Europe
7.5 Asia-Pacific
7.6 Rest of the World
Chapter 8 Patents
Chapter 9 Company Profiles
ABBOTT LABORATORIES
ABBVIE INC.
ADVANCED CELL DIAGNOSTICS INC.
AGILENT TECHNOLOGIES
ARTIVION INC.
BECTON, DICKINSON AND CO.
BENITEC BIOPHARMA LTD.
CALADRIUS BIOSCIENCES
CELGENE CORP.
COMMENCE BIO
DEPUY SYNTHES (J&J)
DRAGERWERK AG & CO. KGAA
EPIC SCIENCES INC.
GENEXINE
GERON
ILLUMINA INC.
IMMUNOCELLULAR THERAPEUTICS
INEX INNOVATIONS EXCHANGE PTE. LTD.
INIVATA LTD.
INTERPACE DIAGNOSTICS LLC
INVIVOSCRIBE INC.
MEDTRONIC PLC
MERCK KGAA
NOVARTIS AG
ONCOCYTE CORP.
ONCOMED PHARMACEUTICALS INC.
PLURISTEM THERAPEUTICS INC.
SILICON BIOSYSTEMS S.P.A
SPHERE FLUIDICS LTD.
THERMO FISHER SCIENTIFIC
VITATEX INC.
List of Tables
Summary Table : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 1 : Large-Scale Initiatives: Cancer Diagnostics Industry
Table 2 : Liquid Biopsy Biomarker Classes
Table 3 : Key Trends in the Market for Next-Generation Cancer Diagnostics
Table 4 : Next-Generation Cancer Diagnostics Industry Subsectors
Table 5 : Diagnostic Market Segments
Table 6 : Next-Generation Diagnostics: Key Analysis Platforms
Table 7 : Analysis Platforms and Biomarker Types
Table 8 : DNA Microarray Technologies in Cancer Diagnostics
Table 9 : Design Features of Protein Microarray Technologies
Table 10 : Microfluidic LOAC Types Used in Cancer Diagnostics
Table 11 : Advanced Sequencing Technologies
Table 12 : Illumina Next Generation Sequencing Workflow
Table 13 : Thermo Fisher Scientific's Next-Generation Sequencing Workflow
Table 14 : Main Ingredients of PCR Technology
Table 15 : PCR Process
Table 16 : Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 17 : Liquid Biopsy: Forces Driving Growth, 2020
Table 18 : Limitations of Solid Biopsy in Cancer Applications
Table 19 : Low-Frequency Mutation Detection
Table 20 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 21 : Global Market for Next-Generation Cancer Diagnostics, by Purpose of Analysis, Through 2027
Table 22 : MRI and Liquid Biopsy Methods
Table 23 : Early Detection: Tissue of Origin Approaches
Table 24 : Global Market for Next-Generation Cancer Diagnostics, by Test Platform, Through 2027
Table 25 : FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 26 : Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 27 : Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 28 : Global Market for Next-Generation Cancer Screening/Early Detection, by Cancer Site, Through 2027
Table 29 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 30 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 31 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 32 : Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2027
Table 33 : Global Market for Digestive Cancer Diagnostics, by Analysis Method, Through 2027
Table 34 : Global Market for Respiratory and Skin Cancer Diagnostics, by Analysis Method, Through 2027
Table 35 : Bladder Cancer Diagnostic Tests, 2020
Table 36 : Brain Cancer: Next-Generation Diagnostics Tests, 2020
Table 37 : Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification
Table 38 : Breast Cancer MDx Technology Platforms
Table 39 : Next-Generation Breast Cancer Tests, 2020
Table 40 : Next-Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests
Table 41 : Ovarian Cancer Early Screening Formats, 2020
Table 42 : Ovarian Cancer: Next-Generation Diagnostics Tests, 2020
Table 43 : CRC Screening Tests
Table 44 : Colorectal Cancer: Next-Generation Diagnostic Tests
Table 45 : Cancer Unknown Primary: Next-Generation Diagnostic Tests, 2020
Table 46 : Gastric Cancer: Next-Generation Diagnostic Tests, 2020
Table 47 : Kidney Cancer: Next-Generation Diagnostic Tests, 2020
Table 48 : Leukemia and Myeloma: Next-Generation Diagnostic Tests, 2020
Table 49 : Liver Cancer: Next-Generation Diagnostic Tests, 2020
Table 50 : Five-Year Survival Rates for Non-Small Cell Lung Cancer
Table 51 : Lung Cancer: Next-Generation Diagnostic Tests, 2020
Table 52 : Lymphoma: Next-Generation Diagnostic Tests, 2020
Table 53 : Melanoma: Next-Generation Diagnostic Tests, 2021
Table 54 : Pan-Cancer: Next-Generation Diagnostic Tests, 2020
Table 55 : Prostate Cancer Next-Generation Diagnostic Tests
Table 56 : Thyroid Cancer: Next-Generation Diagnostics Tests, 2020
Table 57 : R&D: Next-Generation Cancer Diagnostics
Table 58 : Population Sequencing Projects
Table 59 : Global Market for Next-Generation Cancer Diagnostics, by Region, Through 2027
Table 60 : Select Patent Applications Filed on Next-Generation Cancer Diagnostics Technologies
Table 61 : Abbott Laboratories: Product Portfolio
Table 62 : Abbott Laboratories: Developments 2020-2022
Table 63 : AbbVie: Oncology Pharmaceutical Products Portfolio
Table 64 : AbbVie: Marketed Products
Table 65 : AbbVie: Key Developments, 2020-2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Advanced Cell Diagnostics: Product Portfolio
Table 68 : Agilent Technologies: Developments, 2019-2022
Table 69 : Artivion Inc.: Product Portfolio
Table 70 : Artivion Inc.: Developments, 2020
Table 71 : Becton, Dickinson and Co.: Company Financials, 2021
Table 72 : Becton, Dickinson and Co.: Product Portfolio
Table 73 : Becton, Dickinson and Co.: Developments, 2017-2022
Table 74 : Benitec Biopharma: Product Portfolio
Table 75 : Caladrius Biosciences: Product Portfolio
Table 76 : Celgene Corp.: Product Portfolio
Table 77 : Commence Bio: Product Portfolio
Table 78 : DePuy Synthes: Product Portfolio
Table 79 : DePuy Synthes: Developments, 2019-2022
Table 80 : Drager: Product Portfolio
Table 81 : Epic Sciences: Product Portfolio
Table 82 : Genexine: Product Portfolio
Table 83 : Geron: Product Portfolio
Table 84 : ImmunoCellular Therapeutics: Product Portfolio
Table 85 : Medtronic plc: Developments, 2019-2022
Table 86 : Novartis: Developments, 2019 and 2020
Table 87 : OncoCyte: Product Portfolio
Table 88 : OncoMed: Product Portfolio
Table 89 : Pluristem Therapeutics: Product Portfolio
Table 90 : Silicon Biosystems: Product Portfolio
Table 91 : Sphere Fluidics: Product Portfolio
Table 92 : Thermo Fisher Scientific: Product Portfolio
Table 93 : Thermo Fisher Scientific: Developments, 2019-2022
Table 94 : Vitatex: Product Portfolio
List of Figures
Summary Figure : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, 2019-2027
Figure 1 : Distribution of Cases by Stage at Diagnosis: Female Breast Cancer, 2021
Figure 2 : Global Incidence and Prevalence of Cancer Cases, by Cancer Site, 2022
Figure 3 : Snapshot of Next-Generation Cancer Diagnostics Technologies, by Region
Figure 4 : Global Market Shares of Next-Generation Cancer Diagnostics Technologies, by Region, 2027
Figure 5 : Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2021
Figure 6 : Illumina Inc.: Annual Revenue, 2018-2021
Figure 7 : Illumina Inc.: Revenue Share, by Region/Country, 2021
Figure 8 : Illumina Inc.: Revenue Share, by Product Segment, 2021
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security